Phenibutum

General characteristics. Structure:

Active agent: aminophenyl-butyric acid a hydrochloride (Phenibutum) — 250 mg.

Excipients: cellulose microcrystallic — 60,0 mg; croscarmellose sodium — 8,0 mg; potato starch — 24,0 mg; povidone (polyvinylpirrolidone) — 15,0 mg; calcium stearate — 3,0 mg.

Pharmacological properties:

Pharmacodynamics. Nootropic means, facilitates GAMK-oposredovannuyu transfer of nervous impulses in the central nervous system (direct impact on GAMK-ergichesky receptors). Tranquilizing action is combined with the activating effect. Also possesses antiagregantny, antioxidant and some anticonvulsant action.
Improves a functional condition of a brain due to normalization of his metabolism and influence on a brain blood stream (increases volume and linear speed, reduces vascular resistance, improves microcirculation, has antiagregantny effect). Extends stage of latency and shortens duration and expressiveness of a nystagmus. Does not influence on well-cared and adrenoceptors. Reduces vazovegetativny symptoms (including a headache, heavy feeling in the head, sleep disorders, irritability, emotional lability). At course reception increases physical and intellectual effeciency (attention, memory, speed and accuracy of sensory-motor reactions). Reduces manifestations of an adynamy (improves health, increases interest and an initiative (motivation of activity)) without sedation or excitement. Promotes decrease in feeling of alarm, tension and concern, normalizes a dream. Does not cause oppression of the central nervous system in people of advanced age, the muscular weakening after-effect most often is absent. Reduces the oppressing influence of ethanol on the central nervous system.

Pharmacokinetics. Absorption is high, well gets into all body tissues and through a blood-brain barrier (about 0,1% of the entered drug dose, and at persons of young and advanced age in much bigger degree get into tissues of a brain). It is evenly distributed in a liver and kidneys. It is metabolized in a liver — 80-95%, metabolites are pharmacological not active. Does not kumulirut. In 3 h it begins to be removed by kidneys, at the same time concentration in tissue of a brain does not decrease and found during 6 h. About 5% are removed by kidneys in an invariable look, partially with bile.

Indications to use:

astenichesky and alarming and neurotic states.
zaikaniye, tics and enuresis at children.
bessonnitsa and night alarm at elderly.
♦болезнь Menyera, the dizzinesses connected with dysfunctions of a vestibular analyzer of various genesis; prevention of a motion desease at kinetoza.
♦ as a part of complex therapy at treatment of an alcoholic abstinence syndrome, for stopping of psychopathological and somatovegetativny frustration.

Route of administration and doses:

Inside after food 2-3-week courses.
To adults and children since 14 years on 250-500 mg 3 times a day (the maximum daily dose of 2500 mg). To children from 3rd to 8 years on 50-100 mg 3 times a day; from 8 to 14 years — on 250 mg 3 times a day.
The single maximum dose at adults and children from 14 years makes 750 mg, at persons 60 years — 500 mg are more senior, children up to 8 years have 150 mg, from 8 to 14 years — 250 mg. Alcoholic abstinence syndrome: 250-500 mg 3 times a day and for night of 750 mg, with gradual decrease in a daily dose to usual for adults. Treatment of dizziness at dysfunctions of a vestibular mechanism and Menyer's disease: 250 mg 3 times a day for 14 days.
Motion desease prevention: 250-500 mg once in 1 hour prior to the estimated beginning of rolling or at emergence of the first symptoms of a sea sickness. The antirocking to sleep action of Phenibutum amplifies at increase in a dose of drug. At approach of the expressed displays of seasickness (vomiting, etc.) purpose of Phenibutum is ineffective even in doses of 750-1000 mg.

Features of use:

At prolonged use it is necessary to control periodically indicators of function of a liver and peripheral blood. It is necessary to abstain from potentially dangerous types of activity requiring special attention.

Side effects:

Drowsiness, nausea. Irritability strengthening, excitement, alarm, dizziness, a headache (at the first receptions), allergic reactions.

Interaction with other medicines:

Extends and strengthens action of somnolent, narcotic analgetics, neuroleptics, protivoparkinsonichesky and antiepileptic means.

Contraindications:

Hypersensitivity, pregnancy, breastfeeding, children's age up to 3 years.

With CARE at an erosive canker of digestive tract, a liver failure.

Overdose:

Symptoms: strengthening of expressiveness of side effects; the expressed drowsiness, nausea, vomiting, fatty dystrophy of a liver (reception more than 7 g), an eosinophilia, a lowering of arterial pressure, a renal failure.
Treatment: gastric lavage, reception of absorbent carbon and performing symptomatic therapy.

Storage conditions:

List B. To store in the dry, protected from light place, at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets of 250 mg.
On 10 tablets in a blister strip packaging from a film of the polyvinyl chloride and printing aluminum foil varnished. On 10, 20, 30, 40, 50 or 100 tablets in a container polymeric for medicines. One container or 1, 2, 3, 4, 5 or 10 blister strip packagings together with the application instruction place in a pack from a cardboard.